ArticleScientific reports2018
Development and assessment of a predictive nomogram for the progression of IgA nephropathy.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis.Immunity, inflammation and disease · 2026Pooled it
- Is hyperuricemia an independent prognostic factor for IgA nephropathy: a systematic review and meta-analysis of observational cohort studies.Renal failure · 2022Pooled it
- Development of a prognostic nomogram for long-term renal function in chronic kidney disease patients on the basis of clinicopathologic parameters.Clinical and experimental nephrology · 2026Article
- Global glomerulosclerosis proportions predict nephropathy progression in IgA nephropathy: a multicenter retrospective analysis with propensity score matching.Renal failure · 2025Article
- Machine learning-based diagnosis and prognosis of IgAN: A systematic review and meta-analysis.Heliyon · 2024Review
- The efficacy and safety of hydroxychloroquine versus leflunomide in patients with IgA nephropathy: a single-center experience.Journal of nephrology · 2024Article
- Article
- Understanding patient needs and predicting outcomes in IgA nephropathy using data analytics and artificial intelligence: a narrative review.Clinical kidney journal · 2023Review
- A novel prognostic nomogram predicts premature failure of kidney allografts with IgA nephropathy recurrence.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Article
- Glomerular deposition of fibrinogen predicts good prognosis of IgA nephropathy: a single-center cohort study.International urology and nephrology · 2023Article
- Hydrogen sulphide mitigates homocysteine-induced apoptosis and matrix remodelling in mesangial cells through Akt/FOXO1 signalling cascade.Cellular signalling · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study is to establish a nomogram for predicting the prognosis of IgA nephropathy (IgAN). Of the 869 IgAN patients, four-fifths were randomly assigned to the development cohort and one-fifth to the validation cohort. The primary outcome was a composite event of either a ≥ 50% reduction in estimated glomerular filtration rate (eGFR), end-stage renal disease or death. The mean follow-up time was 44 months. The Cox regression model identified urinary protein excretion (1-3.5 g/d, HR 11.639, 95% CI 3.601-37.625; ≥ 3.5 g/d, HR 32.435, 95% CI 10.079-104.380), eGFR (G2, HR 5.293, 95% CI 2.011-13.932; G3, HR 15.797, 95% CI 6.584-37.905; G4, HR 34.619, 95% CI 13.887-86.301; G5, HR 217.651, 95% CI 83.807-565.248), hyperuricaemia (HR 7.031, 95% CI 4.126-11.980), mesangial proliferation (HR 36.667, 95% CI 5.098-263.711), segmental glomerulosclerosis (HR 5.122, 95% CI 3.114-8.425), tubular atrophy/interstitial fibrosis (T1, HR 33.351, 95% CI 7.831-142.044; T2, HR 213.888, 95% CI 51.048-896.182), crescents (C1, HR 3.123, 95% CI 1.771-5.510; C2, HR 7.353, 95% CI 3.590-15.062) and glomerulosclerosis (25-49%, HR 3.123, 95% CI 1.771-5.510; ≥ 50%, HR 14.384, 95% CI 8.813-23.479) for developing the nomogram. The C-index was 0.945 (95% CI 0.914-0.976) in both the development and validation cohorts, showing good agreement between the nomogram-predicted probability and actual free-of-progression probability. Thus, our nomogram could accurately predict the progression of IgAN patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.